The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Meta-analysis examining impact of age on pemetrexed (pem) efficacy for the treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
Luis Paz-Ares
Honoraria - Lilly
Annamaria Zimmermann
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Tudor-Eliade Ciuleanu
Honoraria - Lilly
Paul A. Bunn
Consultant or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Roche; Sanofi
Belen San Antonio
Employment or Leadership Position - Lilly
Jonathan Denne
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Nancy Iturria
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
William J. John
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Giorgio Vittorio Scagliotti
Honoraria - AstraZeneca; Lilly; Pfizer; Roche